Trial Profile
An open-label, parallel-group Phase I study to assess safety, tolerability, and pharmacokinetics of single doses of EU-C-001 administered with an apomorphine challenge, or when 90 mg EU-C-001 are administered alone BID for 7 doses in 12-hour intervals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs EU-C 001 (Primary) ; Apomorphine
- Indications Brain injuries; Craniocerebral trauma
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors PresSura Neuro
- 25 Nov 2019 Status changed from not yet recruiting to completed.
- 06 Apr 2018 New trial record